Application of BACE1 immobilized enzyme reactor for the characterization of multifunctional alkaloids from Corydalis cava (Fumariaceae) as Alzheimer's disease targets

Fitoterapia

Volumn 109, Issue , 2016, Pages 241-247

  Chlebek, Jakub ^a   De Simone, Angela ^b   Hoš͗álková, Anna ^a   Opletal, Lubomír ^a   Pérez, Concepción ^c   Pérez, Daniel I ^d   Havlíková, Lucie ^a   Cahlíková, Lucie ^a   Andrisano, Vincenza ^b  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^d CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

BACE1 inhibitors; Corydalis cava alkaloids; Immobilized enzyme reactor; PAMPA assay

Indexed keywords

ALKALOID DERIVATIVE; ALLOCRYPTOPINE; AMYLOID PRECURSOR PROTEIN; ATENOLOL; BERBERINE; BETA SECRETASE 1; CAFFEINE; CANADALINE; CANADINE; CASEIN KINASE IDELTA; CHOLINESTERASE; CORYCAVAMINE; CORYCAVIDINE; CORYDALIS CAVA EXTRACT; CORYNOLINE; CORYPALMINE; DESIPRAMINE; ENOXACIN; ENZYME INHIBITOR; GALANTAMINE; GLYCOGEN SYNTHASE KINASE 3BETA; HYDROCORTISONE; ISOCORYPALMINE; PIROXICAM; PLANT EXTRACT; PROLYL ENDOPEPTIDASE; PROMAZINE; SCOULERINE; TESTOSTERONE; UNCLASSIFIED DRUG; VERAPAMIL; ALKALOID; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; BERBERINE DERIVATIVE; IMMOBILIZED ENZYME; RECOMBINANT PROTEIN; SECRETASE;

ALZHEIMER DISEASE; ARTICLE; BETA SECRETASE 1 IMMOBILIZED ENZYME REACTOR; BLOOD BRAIN BARRIER; CORYDALIS CAVA; DRUG DETERMINATION; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IC50; IMMOBILIZED ENZYME REACTOR; PRIORITY JOURNAL; TRADITIONAL MEDICINE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CORYDALIS; ISOLATION AND PURIFICATION;

ALKALOIDS; ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ACID ENDOPEPTIDASES; BERBERINE ALKALOIDS; BLOOD-BRAIN BARRIER; CORYDALIS; ENZYMES, IMMOBILIZED; HUMANS; RECOMBINANT PROTEINS;

EID: 84956783078     PISSN: 0367326X     EISSN: 18736971     Source Type: Journal    
DOI: 10.1016/j.fitote.2016.01.008     Document Type: Article

References (51)

1. D.J. Selkoe Alzheimer's disease: genes, proteins, and therapy Physiol. Rev. 81 2001 741 766
2. T.C. Saido Degradation of amyloidbeta peptide: a key to Alzheimer pathogenesis, prevention and therapy Neurosci. News 3 2000 52 62
3. S.Y. Park Potential therapeutic agents against Alzheimer's disease from natural sources Arch. Pharm. Res. 33 2010 1589 1609
4. H.O. Tayeb, H.D. Yang, B.H. Price, and F.I. Tarazi Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors Pharmacol. Ther. 134 2012 8 25
5. M.S. Wolfe APP, Notch, and presenilin: molecular pieces in the puzzle of Alzheimer's disease Int. Immunopharmacol. 2 2002 1919 1929
6. Y. Luo, B. Bolon, S. Kahn, B.D. Bennett, S.B. Khan, P. Denis, W. Fan, H. Kha, J. Zhang, Y. Gong, L. Martin, J.C. Louis, Q. Yan, W.G. Richards, M. Citron, and R. Vassar Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation Nat. Neurosci. 4 2001 231 232
7. Y. Ihara, N. Nukina, R. Miura, and M. Ogawara Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease J. Biochem. 99 1986 1807 1810
8. F. Plattner, M. Angelo, and K.P. Giese The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation J. Biol. Chem. 281 2006 25457 25465
9. P. Cohen, D. Yellowlees, A. Aitken, A. Donella-Deana, B.A. Hemmings, and P.J. Parker Separation and characterisation of glycogen synthase kinase 3, glycogen synthase kinase 4 and glycogen synthase kinase 5 from rabbit skeletal muscle Eur. J. Biochem. 124 1982 21 35
10. G.V. Rayasam, V.K. Tulasi, R. Sodhi, J.A. Davis, and A. Ray Glycogen synthase kinase 3: more than a namesake Br. J. Pharmacol. 156 2009 885 898
11. A. Kannoji, S. Phukan, V.S. Babu, and V.N. Balaji GSK3β: a master switch and a promising target Expert Opin. Ther. Targets 12 2008 1443 1455
12. C. Hooper, R. Killick, and S. Lovestone The GSK3 hypothesis of Alzheimer's disease J. Neurochem. 104 2008 1433 1439
13. D.P. Hanger, H.L. Byers, S. Wray, K.Y. Leung, M.J. Saxton, A. Seereeram, C.H. Reynolds, M.A. Ward, and B.H. Anderton Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis J. Biol. Chem. 282 2007 23645 23654
14. A. Agis-Torres, M. Söllhuber, M. Fernandez, and J.M. Sanchez-Montero Multi-target-directed ligands and other therapeutic strategies in the search of a real solution for Alzheimer's disease Curr. Neuropharmacol. 12 2014 2 36
15. L. Piazzi, A. Cavalli, F. Colizzi, F. Belluti, M. Bartolini, F. Mancini, M. Recanatini, V. Andrisano, and A. Rampa Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds Bioorg. Med. Chem. Lett. 18 2008 423 426
16. R. León, A.G. García, and J. Marco-Contelles Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease Med. Res. Rev. 33 2013 139 189
17. M. Decker Recent advances in the development of hybrid molecules/designed multiple compounds with antiamnesic properties Mini-Rev. Med. Chem. 7 2007 221 229
18. J. Fang, Y. Li, R. Liu, X. Pang, C. Li, R. Yang, Y. He, W. Lian, A.L. Liu, and G.H. Du Discovery of multitarget-directed ligands against Alzheimer's disease through systematic prediction of chemical-protein interactions J. Chem. Inf. Model. 55 2015 149 164
19. A. Cavalli, M.L. Bolognesi, A. Minarini, M. Rosini, V. Tumiatti, M. Recanatini, and C. Melchiorre Multi-target-directed ligands to combat neurodegenerative diseases J. Med. Chem. 51 2008 347 372
20. I. Orhan, B. Sener, M.I. Choudhary, and A. Khalid Acetylcholinesterase and butyrylcholinesterase inhibitory activity of some Turkish medicinal plants J. Ethnopharmacol. 91 2004 57 60
21. A. Andersen, B. Gauguin, L. Gudiksen, and A.K. Jäger Screening of plants used in Danish folk medicine to treat memory dysfunction for acetylcholinesterase inhibitory activity J. Ethnopharmacol. 104 2006 418 422
22. V. Preininger, R.S. Thakur, and F. Šantavý Isolation and chemistry of alkaloids from plants of the family Papaveraceae LXVII: Corydalis cava (L.) Sch. et K. (C. tuberosa DC) J. Pharm. Sci. 65 1976 294 296
23. J. Slavík, and L. Slavíková Alkaloids from Corydalis cava (L.) SCHW. et KOERTE Collect. Czechoslov. Chem. Commun. 44 1979 2261 2274
24. V. Preininger Chemotaxonomy of Papaveraceae and Fumariaceae A. Brossi, The Alkaloids 29 1986 Academic Press New York 1 98
25. Z. Novák, J. Chlebek, L. Opletal, P. Jiroš, K. Macáková, J. Kuneš, and L. Cahlíková Corylucinine, a new alkaloid from Corydalis cava (Fumariaceae), and its cholinesterase activity Nat. Prod. Commun. 7 2012 859 860
26. J. Chlebek, K. Macáková, L. Cahlíková, M. Kurfürst, J. Kuneš, and L. Opletal Acetylcholinesterase and butyrylcholinesterase inhibitory compounds from Corydalis cava Schweigger. & Korte (Fumariaceae) Nat. Prod. Commun. 6 2011 607 610
27. C.W. Lam, A. Wakeman, A. James, A. Ata, R.M. Gengan, and S.A. Ross Bioactive steroidal alkaloids from Buxus macowanii Oliv Steroids 95 2015 73 79
28. H. Zhang, M.M. Conte, Z. Khalil, X.C. Huang, and R. Capon New dictyodendrins as BACE inhibitors from a southern Australian marine sponge, Ianthella sp RSC Adv. 2 2012 4209 4214
29. H.A. Jung, B.S. Min, T. Yokozawa, J.H. Lee, Y.S. Kim, and J.S. Choi Anti-Alzheimer and antioxidant activities of Coptidis Rhizoma alkaloids Biol. Pharm. Bull. 32 2009 1433 1438
30. V. Mani, K. Ramasamy, A. Ahmad, M. Parle, S.A.A. Shah, and A.B.A. Majeed Protective effects of total alkaloidal extract from Murraya koenigii leaves on experimentally induced dementia Food Chem. Toxicol. 50 2012 1036 1044
31. M. Alonso, and A. Martinez GSK-3 inhibitors: discoveries and developments Curr. Med. Chem. 11 2004 753 761
32. D.P. Hanger, H.L. Byers, S. Wray, K.Y. Leung, M.J. Saxton, A. Seereeram, C.H. Reynolds, M.A. Ward, and B.H. Anderton Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis J. Biol. Chem. 282 2007 23645 23654
33. F. Mancini, A. De Simone, and V. Andrisano Beta-secretase as a target for Alzheimer's disease drug discovery: an overview of in vitro methods for characterization of inhibitors Anal. Bioanal. Chem. 400 2011 1979 1996
34. F. Mancini, and V. Andrisano Development of a liquid chromatographic system with fluorescent detection for β-secretase immobilized enzyme reactor on-line enzymatic studies J. Pharm. Biomed. Anal. 52 2010 355 361
35. A. De Simone, F. Mancini, S. Cosconati, L. Marinelli, V. La Pietra, E. Novellino, and V. Andrisano Human recombinant beta-secretase immobilized enzyme reactor for fast hits J. Pharm. Biomed. Anal. 73 2013 131 134
36. P.A. Nielsen, O. Andersson, S.H. Hansen, K.B. Simonsen, and G. Andersson Models for predicting blood-brain barrier permeation Drug Discov. Today 16 2011 472 475
37. L. Di, E.H. Kerns, K. Fan, O.J. McConnell, and G.T. Carter High throughput artificial membrane permeability assay for blood-brain barrier Eur. J. Med. Chem. 38 2003 223 232
38. M. Bartolini, N.H. Greig, Q.S. Yu, and V. Andrisano Immobilized butyrylcholinesterase in the characterization of new inhibitors that could ease Alzheimer's disease J. Chromatogr. A 1216 2009 2730 2738
39. M. Bartolini, V. Cavrini, and V. Andrisano Choosing the right chromatographic support in making a new acetylcholinesterase-micro-immobilised enzyme reactor for drug discovery J. Chromatogr. A 1065 2005 135 144
40. S.Y. Jeon, K. Bae, Y.H. Seong, and K.S. Song Green tea catechins as a BACE1 (betasecretase) inhibitor Bioorg. Med. Chem. Lett. 13 2003 3905 3908
41. F. Gruninger-Leitch, D. Schlatter, E. Kung, P. Nelbock, and H. Dobeli Substrate and inhibitor profile of BACE (beta-secretase) and comparison with other mammalian aspartic proteases J. Biol. Chem. 277 2002 4687 4693
42. S.J. Stachel, C.A. Coburn, T.G. Steele, K.G. Jones, E.F. Loutzenhiser, A.R. Gregro, H.A. Rajapakse, M.T. Lai, M.C. Crouthamel, M. Xu, K. Tugusheva, J.E. Lineberger, B.L. Pietrak, A.S. Espeseth, X.P. Shi, E. Chen-Dodson, M.K. Holloway, S. Munshi, A.J. Simon, L. Kuo, and J.P. Vacca Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1) J. Med. Chem. 47 2004 6447 6450
43. V. Palomo, D.I. Perez, C. Perez, J.A. Morales-Garcia, I. Soteras, S. Alonso-Gil, A. Encinas, A. Castro, N.E. Campillo, A. Perez Castillo, C. Gil, and A. Martinez 5-Imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3 J. Med. Chem. 55 2012 1645 1661
44. D.I. Perez, C. Gil, and A. Martinez Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases Med. Res. Rev. 31 2011 924 954
45. L. Cahlíková, D.I. Perez, Š. Štěpánková, J. Chlebek, M. Šafratová, A. Hoš͗álková, and L. Opletal In vitro inhibitory effects of 8-O-demethylmaritidine and undulatine on acetylcholinesterase, and their predicted penetration across the blood-brain barrier J. Nat. Prod. 78 2015 1189 1192
46. L. Cahlíková, L. Hulová, M. Hrabinová, J. Chlebek, A. Hoš͗álková, M. Adamcová, M. Šafratová, D. Jun, L. Opletal, M. Ločárek, and K. Macáková Isoquinoline alkaloids as prolyl oligopeptidase inhibitors Fitoterapia 103 2015 192 196
47. K. Ingkaninan, P. Phengpa, S. Yuenyongsawad, and N. Khorana Acetylcholinesterase inhibitors from Stephania venosa tuber J. Pharm. Pharmacol. 58 2006 695 700
48. N. Khorana, S. Markmee, K. Ingkaninan, S. Ruchirawat, R. Kitbunnadaj, and M.R. Pullagurla Evaluation of a new lead for acetylcholinesterase inhibition Med. Chem. Res. 18 2009 231 241
49. W. Blaschek, U. Hilgenfeldt, U. Holzgrabe, J. Reichling, P. Ruth, and V. Schulz Corydalis cava. Hager ROM 2011, Version 10:3 2011 Springer Verlag
50. A. Adsersen, A. Kjølbye, O. Dall, and A.K. Jäger Acetylcholinesterase and butyrylcholinesterase inhibitory compounds from Corydalis cava Schweigg. & Kort Ethnopharmacol. 113 2007 179 182
51. A. Baki, A. Bielik, L. Molnár, G. Szendrei, and G.M. Keserü A high throughput luminescent assay for glycogen synthase kinase-3β inhibitors Assay Drug Dev. Technol. 5 2007 75 78